Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 7.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 657,355 shares of the biotechnology company’s stock after selling 50,011 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Anika Therapeutics were worth $10,820,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Anika Therapeutics in the fourth quarter valued at approximately $27,000. Wells Fargo & Company MN boosted its position in Anika Therapeutics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 1,759 shares during the period. Los Angeles Capital Management LLC boosted its position in Anika Therapeutics by 9.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 980 shares during the period. ExodusPoint Capital Management LP acquired a new position in shares of Anika Therapeutics in the fourth quarter worth $264,000. Finally, XTX Topco Ltd purchased a new stake in shares of Anika Therapeutics during the fourth quarter worth $352,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Stock Down 21.0 %

Shares of ANIK opened at $11.64 on Friday. The company has a market capitalization of $166.93 million, a price-to-earnings ratio of -1.75 and a beta of 0.76. Anika Therapeutics, Inc. has a 52-week low of $11.48 and a 52-week high of $29.12. The stock has a 50 day moving average price of $14.80 and a 200 day moving average price of $16.54.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.37). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. On average, equities analysts anticipate that Anika Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. B. Riley assumed coverage on Anika Therapeutics in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. StockNews.com raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, Barrington Research lowered their price target on shares of Anika Therapeutics from $25.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, March 13th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.